{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:31:45Z","timestamp":1786516305185,"version":"build-2736575974"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the adverse reactions associated with ibuprofen, one of the most widely used analgesic-antipyretic agents, in comparison with other nonsteroidal anti-inflammatory drugs (NSAIDs). In Romania, most pharmaceutical forms of ibuprofen are available over the counter, except for parenteral formulations and high-dose oral forms (800\u00a0mg), which require a prescription.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Descriptive and disproportionality methods were conducted on reports associated with ibuprofen and six other NSAIDs, submitted to the National Agency for Medicines and Medical Devices of Romania between 2015 and 2024 by healthcare professionals and patients. The type and the frequency of adverse reactions, and their classification according to the System Organ Classification were analyzed. For the disproportionality analysis, the reporting odds ratio and 95% confidence interval were used to compare the disproportional reporting ADRs related to ibuprofen with that of other six NSAIDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From the total number of reports (n = 128), 44 were related to ibuprofen, with an annual mean of 4.4 \u00b1 2.91, indicating greater reporting variability. Within 15 reports, several serious events were recorded 10 required hospitalization or prolongation of hospitalization, 5 were life-threatening, 3 were associated with other severe medical conditions, and one resulted in the patients\u2019 death. The safety profile of ibuprofen shows a predominance of gastrointestinal adverse reactions (n = 31) over immunological (n = 18), cutaneous (n = 18), or neurological reactions (n = 7). However, the disproportionality analysis, limited by the relatively small number of reports, suggests a higher disproportional reporting of gastrointestinal disorders for ibuprofen than for etoricoxib (ROR 4.74; 95% CI 1.72\u201313.03). In contrast, a lower disproportional reporting skin and soft tissue ADRs related to ibuprofen, compared with diclofenac (ROR 0.32; 95% CI 0.11\u20130.95) and celecoxib (ROR 0.17; 95% CI 0.05\u20130.54), was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The reported adverse reactions were consistent with the established safety profile of ibuprofen and are largely described in the Summary of Product Characteristics, with no new safety signals identified. However, this study adds national real-world pharmacovigilance evidence by demonstrating a higher disproportional reporting of gastrointestinal disorders compared with etoricoxib and by highlighting children and adolescents as the most frequently represented reporting population. These findings contribute to a better understanding of ibuprofen safety patterns in routine clinical practice in Romania. The results should be interpreted in the context of inherent limitations, such as underreporting of adverse reactions and the difficulty in establishing causality, particularly for patient-reported cases, which may introduce a higher degree of subjectivity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1863824","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:59:50Z","timestamp":1786514390000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety assessment for ibuprofen using disproportionality analysis: a decade of data from the Romanian national pharmacovigilance system"],"prefix":"10.3389","volume":"17","author":[{"given":"Cristina Anamaria","family":"Buciuman","sequence":"first","affiliation":[{"name":"Inspection Department, National Agency for Medicines and Medical Devices of Romania","place":["Bucharest, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Butuca","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu","place":["Sibiu, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Frum","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu","place":["Sibiu, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia Gabriela","family":"Gligor","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu","place":["Sibiu, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Ganea","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea","place":["Oradea, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Gra\u021biela","family":"Vica\u015f","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea","place":["Oradea, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Marian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea","place":["Oradea, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavia","family":"Gligor","sequence":"additional","affiliation":[{"name":"Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea","place":["Oradea, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Maximiliana","family":"Dobrea","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu","place":["Sibiu, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina Florentina","family":"Moisa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea","place":["Oradea, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Pallag","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea","place":["Oradea, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Jurca","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea","place":["Oradea, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudiu","family":"Morgovan","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu","place":["Sibiu, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1111\/jth.15493","article-title":"Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: thrombosis at unusual sites","volume":"19","author":"Abbattista","year":"2021","journal-title":"J. Thrombosis Haemostasis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.24875\/gmm.m24000889","article-title":"Prescription of non-steroidal anti-inflammatory and antirheumatic drugs in outpatient hypertensive patients","volume":"160","author":"Agui\u00f1aga-Mart\u00ednez","year":"2024","journal-title":"Gac. Med. Mex."},{"key":"B3","unstructured":"ANMDMR \u2013 Agenia naional\u0103 a medicamentului \u015fi a dispozitivelor medicale din Rom\u00e2nia\n          \n          \n          2026"},{"key":"B4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.envres.2022.112777","article-title":"Ibuprofen exposure in Europe; ePiE as an alternative to costly environmental monitoring","volume":"209","author":"Austin","year":"2022","journal-title":"Environ. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.23736\/S0026-4946.18.05453-1","article-title":"Ibuprofen in the treatment of children\u2019s inflammatory pain: a clinical and pharmacological overview","volume":"71","author":"Barbagallo","year":"2019","journal-title":"Minerva Pediatr."},{"key":"B6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3390\/METABO15090576","article-title":"A surveillance of paracetamol and nonsteroidal anti-inflammatory drug consumption in cluj-napoca, Romania, using wastewater-based epidemiology","volume":"15","author":"Beldean-Galea","year":"2025","journal-title":"Metabolites"},{"key":"B7","doi-asserted-by":"publisher","first-page":"439385","DOI":"10.3389\/FPED.2019.00517\/TEXT","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) systemic use: the risk of renal failure","volume":"7","author":"Bensman","year":"2020","journal-title":"Front. Pediatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3390\/MOLECULES28041945","article-title":"New NSAID conjugates as potent and selective COX-2 inhibitors: synthesis, molecular modeling and biological investigation","volume":"28","author":"Bokhtia","year":"2023","journal-title":"Molecules"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3390\/PH18091301","article-title":"Pharmacovigilance insights into ibuprofen\u2019s neuropsychiatric safety: a retrospective analysis of EudraVigilance reports","volume":"18","author":"Buciuman","year":"","journal-title":"Pharmaceuticals"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3390\/ph18071045","article-title":"Exploring the cardiovascular safety profile of ibuprofen: insights from EudraVigilance database","volume":"18","author":"Buciuman","year":"","journal-title":"Pharm. (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3390\/PH19020319","article-title":"Contributions of pharmacovigilance to the understanding of risks associated with ibuprofen: descriptive and disproportionality analysis using FAERS data","volume":"19","author":"Buciuman","year":"2026","journal-title":"Pharmaceuticals"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3390\/BIOMEDICINES12051124","article-title":"An assessment of semaglutide safety based on real world data: from popularity to spontaneous reporting in EudraVigilance database","volume":"12","author":"Butuca","year":"2024","journal-title":"Biomedicines"},{"key":"B13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2147\/JAA.S267005","article-title":"NSAID hypersensitivity in the pediatric population: classification and diagnostic strategies","volume":"15","author":"Cavkaytar","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/S40265-017-0751-Z","article-title":"Working towards an appropriate use of ibuprofen in children: an evidence-based appraisal","volume":"77","author":"de Martino","year":"2017","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/ph17101278","article-title":"Drug\u2013drug interactions of selective serotonin reuptake inhibitors: a pharmacovigilance study on real-world evidence from the EudraVigilance database","volume":"17","author":"Dobrea","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.4103\/JFMPC.JFMPC_201_20","article-title":"NSAIDs and self-medication: a serious concern","volume":"9","author":"Doomra","year":"2020","journal-title":"J. Fam. Med. Prim. Care"},{"key":"B18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40360-021-00520-y","article-title":"Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs","volume":"22","author":"Dubrall","year":"2021","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B19","unstructured":"European database of suspected adverse drug reaction reports - monitoring in the EU\n          \n          \n          2026"},{"key":"B20","volume-title":"Screening for adverse reactions in EudraVigilance","year":"2016"},{"key":"B57","unstructured":"United Kingdom\n          Reckitt Benckiser Healthcare (UK) Ltd.\n          Nurofen 200 mg Tablets Summary of Product Characteristics Updated 09-Jul-2026\n          \n          2026"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2559479","DOI":"10.1001\/jamanetworkopen.2025.59479","article-title":"Prevalence of over-the-counter and prescription medication use in the US","volume":"9","author":"Green","year":"2026","journal-title":"JAMA Netw. Open"},{"key":"B22","unstructured":"Help to shape the MedDRA terminology | MedDRA\n          \n          \n          2026"},{"key":"B23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/J.GASTRE.2021.06.002","article-title":"NSAIDs, gastrointestinal toxicity and inflammatory bowel disease","volume":"45","author":"Hijos-Mallada","year":"2022","journal-title":"Gastroenterol. Y Hepatol. English Ed."},{"key":"B24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/IJMS22126637","article-title":"Novel applications of NSAIDs: insight and future perspectives in cardiovascular, neurodegenerative, diabetes and cancer disease therapy","volume":"22","author":"Kadu\u0161evi\u010dius","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/XEB.0000000000000173","article-title":"Evaluation of prescribing patterns of nonsteroidal anti-inflammatory agents in a tertiary setting","volume":"17","author":"Khalil","year":"2019","journal-title":"Int. J. Evid. Based Healthc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1007\/S12325-023-02481-6","article-title":"Non-steroidal anti-inflammatory drugs: clinical implications, renal impairment risks, and AKI","volume":"40","author":"LaForge","year":"2023","journal-title":"Adv. Ther."},{"key":"B27","unstructured":"ANMDMR - Nomenclatorul Medicamentelor Pentru Uz Uman\n          \n          \n          2026"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40264-016-0453-6","article-title":"Patient reporting of adverse drug reactions: an international survey of national competent authorities\u2019 views and needs","volume":"39","author":"Matos","year":"2016","journal-title":"Drug Saf."},{"key":"B29","unstructured":"Medcalc\u2019s Odds Ratio Calculator\n          \n          \n          2026"},{"key":"B30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.15586\/AEI.V50ISP2.784","article-title":"Etiological causes in patients with acute urticaria and angioedema: a cross-sectional study","volume":"50","author":"Melikoglu","year":"2022","journal-title":"Allergol. Immunopathol. Madr."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e70283","DOI":"10.1111\/jep.70283","article-title":"Silent dangers in elderly pharmacotherapy: the interplay of polypharmacy, multimorbidity, and drug interactions","volume":"31","author":"Ngcobo","year":"2025","journal-title":"J. Eval. Clin. Pract."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.3390\/pharmaceutics13101531","article-title":"Verification of the \u201cupward variation in the reporting odds ratio scores\u201d to detect the signals of drug-drug interactions","volume":"13","author":"Noguchi","year":"2021","journal-title":"Pharmaceutics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1136\/ard-2023-224339","article-title":"Major adverse cardiovascular events and mortality with opioids versus NSAIDs initiation in patients with rheumatoid arthritis","volume":"82","author":"Ozen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.1021\/acs.molpharmaceut.8b00736","article-title":"Liking the gastrointestinal behavior of ibuprofen with the systemic exposure between and within humans\u2014part 2: Fed state","volume":"15","author":"Paix\u00e3o","year":"2018","journal-title":"Mol. Pharm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"113598","DOI":"10.1016\/J.FCT.2022.113598","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs): a current insight into its molecular mechanism eliciting organ toxicities","volume":"172","author":"Panchal","year":"2023","journal-title":"Food Chem. Toxicol."},{"key":"B35","first-page":"17","article-title":"Perception on adverse drug reaction reporting by physicians working in southern Romania","volume":"8","author":"Paveliu","year":"2013","journal-title":"Maedica (Bucur)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2174\/1573396317666210909152831","article-title":"Adverse drug reactions of acetaminophen and ibuprofen in the paediatric population: analysis of the Italian spontaneous reporting database","volume":"18","author":"Pelliccia","year":"2021","journal-title":"Curr. Pediatr. Rev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/S10787-009-0016-X","article-title":"Ibuprofen: pharmacology, efficacy and safety","volume":"17","author":"Rainsford","year":"2009","journal-title":"Inflammopharmacology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/PDS.3687","article-title":"Adverse drug reaction reports of patients and healthcare professionals-differences in reported information","volume":"24","author":"Rolfes","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B39","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","article-title":"Cardiovascular effects and safety of (non-aspirin) NSAIDs","volume":"17","author":"Schjerning","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e6425","DOI":"10.7759\/CUREUS.6425","article-title":"Ibuprofen-induced anaphylactic shock in adult Saudi patient","volume":"11","author":"Shaikhain","year":"2019","journal-title":"Cureus"},{"key":"B41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/ijerph19010413","article-title":"The importance of direct patient reporting of adverse drug reactions in the safety monitoring process","volume":"19","author":"Sienkiewicz","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e37080","DOI":"10.7759\/cureus.37080","article-title":"Effects of non-steroidal anti-inflammatory drugs (Nsaids) and gastroprotective nsaids on the gastrointestinal tract: a narrative review","volume":"15","author":"Sohail","year":"2023","journal-title":"Cureus"},{"key":"B43","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1183\/09031936.93.03050588","article-title":"The cyclooxygenase theory of aspirin-induced asthma","volume":"3","author":"Szczeklik","year":"1990","journal-title":"Eur. Respir. J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2165\/00003088-200847110-00002","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib","volume":"47","author":"Takemoto","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10620-012-2443-6","article-title":"Mechanisms behind the increased vulnerability of the aging stomach to NSAID-related injury: perhaps not as simple as we may think","volume":"58","author":"Tang","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.37506\/ijfmt.v15i2.14308","article-title":"NSAID-induced adverse drug reaction: mechanism and management","volume":"15","author":"Tjenggal","year":"2025","journal-title":"Indian J. Forensic Med. and Toxicol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/vaccines9040393","article-title":"Analysis of thrombotic adverse reactions of COVID-19 AstraZeneca vaccine reported to EudraVigilance database","volume":"9","author":"Tobaiqy","year":"2021","journal-title":"Vaccines"},{"key":"B48","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s13052-025-02135-z","article-title":"Adverse reactions to acetaminophen and ibuprofen in pediatric patients: a narrative review","volume":"51","author":"Vassallo","year":"2025","journal-title":"Ital. J. Pediatr."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijerph18041507","article-title":"Adverse drug reaction reporting by patients in 12 European countries","volume":"18","author":"Valinciute-Jankauskiene","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12325-019-01144-9","article-title":"Ibuprofen safety at the golden anniversary: are all NSAIDs the same? A narrative review","volume":"37","author":"Varrassi","year":"2020","journal-title":"Adv. Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.3390\/cancers16223847","article-title":"The descriptive and disproportionality assessment of EudraVigilance database reports on capecitabine induced cardiotoxicity","volume":"16","author":"Vonica","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"105685","DOI":"10.1016\/J.JBSPIN.2023.105685","article-title":"NSAID: current limits to prescription","volume":"91","author":"Wirth","year":"2024","journal-title":"Jt. Bone Spine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.3390\/ijerph19084447","article-title":"Comparison of patient adverse drug reaction reporting systems in nine selected countries","volume":"19","author":"Worakunphanich","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B54","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/S11255-024-04263-7","article-title":"Renal injury in NSAIDs: a real-world analysis based on the FAERS database","volume":"57","author":"Xu","year":"2024","journal-title":"Int. Urology Nephrol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s40272-022-00514-1","article-title":"Efficacy and safety of NSAIDs in infants: a comprehensive review of the literature of the past 20 years","volume":"24","author":"Ziesenitz","year":"2022","journal-title":"Pediatr. Drugs"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1863824\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:59:53Z","timestamp":1786514393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1863824\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":57,"alternative-id":["10.3389\/fphar.2026.1863824"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1863824","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1863824"}}